{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T17:51:40Z","timestamp":1784829100982,"version":"3.55.0"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceutica","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.ejca.2024.114183","type":"journal-article","created":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T23:36:41Z","timestamp":1718667401000},"page":"114183","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Adjustment for imbalances in baseline characteristics in the MAGNITUDE phase 3 study confirms the clinical benefit of niraparib in combination with abiraterone acetate plus prednisone in patients with metastatic prostate cancer"],"prefix":"10.1016","volume":"209","author":[{"given":"Guilhem","family":"Roubaud","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhardt","family":"Attard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Boegemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Olmos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Trevisan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Antoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie","family":"Pascoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille","family":"Capone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzy","family":"Van Sanden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"Hashim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Palmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Chi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.ejca.2024.114183_bib1","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.3390\/biomedicines9091247","article-title":"Current and emerging therapies for metastatic castration-resistant prostate cancer (mCRPC)","volume":"9","author":"Henr\u00edquez","year":"2021","journal-title":"Biomedicines"},{"issue":"2","key":"10.1016\/j.ejca.2024.114183_bib2","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0227552","article-title":"Overall survival and second primary malignancies in men with metastatic prostate cancer","volume":"15","author":"Meht\u00e4l\u00e4","year":"2020","journal-title":"PloS One"},{"key":"10.1016\/j.ejca.2024.114183_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2024.01.011","article-title":"Treatment patterns and outcomes in metastatic castration-resistant prostate cancer patients with and without somatic or germline alterations in homologous recombination repair genes","author":"Olmos","year":"2024","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2024.114183_bib4","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1053\/ctrv.2000.0210","article-title":"Metastatic bone disease: clinical features, pathophysiology and treatment strategies","volume":"27","author":"Coleman","year":"2001","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ejca.2024.114183_bib5","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s40271-018-0349-x","article-title":"Symptoms and impacts in metastatic castration-resistant prostate cancer: qualitative findings from patient and physician interviews","volume":"12","author":"Holmstrom","year":"2019","journal-title":"Patient-Patient-Cent Outcomes Res"},{"issue":"9","key":"10.1016\/j.ejca.2024.114183_bib6","doi-asserted-by":"crossref","first-page":"E415","DOI":"10.5489\/cuaj.5154","article-title":"Symptom assessment to guide treatment selection and determine progression in metastatic castration-resistant prostate cancer: expert opinion and review of the evidence","volume":"12","author":"Saad","year":"2018","journal-title":"Can Urol Assoc J"},{"key":"10.1016\/j.ejca.2024.114183_bib7","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.6_suppl.9","volume":"39","author":"Rathkopf","year":"2021","journal-title":"J Clin Oncol"},{"issue":"18","key":"10.1016\/j.ejca.2024.114183_bib8","doi-asserted-by":"crossref","first-page":"3339","DOI":"10.1200\/JCO.22.01649","article-title":"Niraparib and abiraterone acetate for metastatic castration-resistant prostate cancer","volume":"41","author":"Chi","year":"2023","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.ejca.2024.114183_bib9","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.annonc.2023.06.009","article-title":"Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial","volume":"34","author":"Chi","year":"2023","journal-title":"Ann Oncol"},{"issue":"7203","key":"10.1016\/j.ejca.2024.114183_bib10","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1136\/bmj.319.7203.185","article-title":"Understanding controlled trials: baseline imbalance in randomised controlled trials","volume":"319","author":"Roberts","year":"1999","journal-title":"BMJ"},{"key":"10.1016\/j.ejca.2024.114183_bib11","doi-asserted-by":"crossref","first-page":"S1326","DOI":"10.1016\/j.annonc.2023.10.087","volume":"34","author":"Chi","year":"2023","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2024.114183_bib12","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/1471-2288-13-99","article-title":"Adjusting for multiple prognostic factors in the analysis of randomised trials","volume":"13","author":"Kahan","year":"2013","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.ejca.2024.114183_bib13","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1007\/s40273-018-0759-6","article-title":"Modeling covariate-adjusted survival for economic evaluations in oncology","volume":"37","author":"Majer","year":"2019","journal-title":"PharmacoEconomics"},{"issue":"7","key":"10.1016\/j.ejca.2024.114183_bib14","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1200\/JCO.2013.52.3696","article-title":"Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer","volume":"32","author":"Halabi","year":"2014","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2024.114183_bib15","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1093\/ckj\/sfab158","article-title":"An introduction to inverse probability of treatment weighting in observational research","volume":"15","author":"Chesnaye","year":"2022","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.ejca.2024.114183_bib16","author":"European Medicines Agency (EMA).","year":"2015","journal-title":"Guideline on adjustment for baseline covariates in clinical trials."},{"key":"10.1016\/j.ejca.2024.114183_bib17","unstructured":"Food and Drug Administration (FDA). Adjusting for Covariates in Randomized Clinical Trials for Drugs and Biological Products: Guidance for Industry; 2023. (Available from: https:\/\/efaidnbmnnnibpcajpcglclefindmkaj\/https:\/\/www.fda.gov\/media\/148910\/download.)."},{"issue":"21","key":"10.1016\/j.ejca.2024.114183_bib18","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1001\/jama.2022.21506","article-title":"Adjustment for Baseline Characteristics in Randomized Clinical Trials","volume":"328","author":"Holmberg","year":"2022","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.ejca.2024.114183_bib19","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.jchf.2022.02.007","article-title":"Covariate adjustment in cardiovascular randomized controlled trials: its value, current practice, and need for improvement","volume":"10","author":"Pirondini","year":"2022","journal-title":"JACC Heart Fail"},{"issue":"5","key":"10.1016\/j.ejca.2024.114183_bib20","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1002\/sim.5991","article-title":"Variance reduction in randomised trials by inverse probability weighting using the propensity score","volume":"33","author":"Williamson","year":"2014","journal-title":"Stat Med"},{"key":"10.1016\/j.ejca.2024.114183_bib21","doi-asserted-by":"crossref","first-page":"l5657","DOI":"10.1136\/bmj.l5657","article-title":"Alternative Approaches for Confounding Adjustment in Observational Studies Using Weighting Based on the Propensity Score: A Primer for Practitioners","volume":"367","author":"Desai","year":"2019","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.ejca.2024.114183_bib22","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.cmpb.2003.10.004","article-title":"Adjusted survival curves with inverse probability weights","volume":"75","author":"Cole","year":"2004","journal-title":"Comput Methods Prog Biomed"},{"issue":"5","key":"10.1016\/j.ejca.2024.114183_bib23","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.eururo.2014.02.056","article-title":"Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302)","volume":"66","author":"Rathkopf","year":"2014","journal-title":"Eur Urol"},{"issue":"7","key":"10.1016\/j.ejca.2024.114183_bib24","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1200\/JCO.2003.06.100","article-title":"Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer","volume":"21","author":"Halabi","year":"2003","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.ejca.2024.114183_bib25","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S1470-2045(21)00402-2","article-title":"Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 study","volume":"22","author":"Saad","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2024.114183_bib26","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jclinepi.2020.10.012","article-title":"Incomparability of treatment groups is often blindly ignored in randomised controlled trials - a post hoc analysis of baseline characteristic tables","volume":"130","author":"Nguyen","year":"2021","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.ejca.2024.114183_bib27","series-title":"Methods for Comparative Individual Patient Data","article-title":"The Use of Observational Data to Inform Estimates of Treatment Effectiveness in Technology Appraisal","author":"Faria","year":"2015"},{"issue":"2","key":"10.1016\/j.ejca.2024.114183_bib28","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s40487-023-00227-6","article-title":"Real-world outcomes following first-line treatment in patients with advanced ovarian cancer with multiple risk factors for disease progression who received maintenance therapy or active surveillance","volume":"11","author":"Chase","year":"2023","journal-title":"Oncol Ther"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804924008396?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804924008396?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T16:46:23Z","timestamp":1729615583000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804924008396"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":28,"alternative-id":["S0959804924008396"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2024.114183","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adjustment for imbalances in baseline characteristics in the MAGNITUDE phase 3 study confirms the clinical benefit of niraparib in combination with abiraterone acetate plus prednisone in patients with metastatic prostate cancer","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2024.114183","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"114183"}}